<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107081</url>
  </required_header>
  <id_info>
    <org_study_id>SPOG 2003 FN</org_study_id>
    <secondary_id>Umbrella Network Trial 2004.3</secondary_id>
    <secondary_id>OCS - 01466-02-2004</secondary_id>
    <nct_id>NCT00107081</nct_id>
  </id_info>
  <brief_title>Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting</brief_title>
  <official_title>A Prospective Multi-Center Study on Pediatric Patients With Fever in Severe Chemotherapy Induced Neutropenia, Including a Randomized Comparison of Outpatient Management and Oral Antimicrobial Therapy Versus Inpatient Management and Intravenous Antimicrobial Therapy in a Subgroup With Low Risk of Adverse Events (Low-Risk Subgroup Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Pediatric Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Cancer League</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Pediatric Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether, in children with cancer presenting with
      fever in severe chemotherapy-induced neutropenia at low risk for medical complications, oral
      antibiotics in an outpatient setting after an initial phase of intravenous antibiotics and
      in-hospital observation for 8 to 22 hours, is not inferior as to safety and efficacy compared
      to continued intravenous antibiotics given in-hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Details on antimicrobial therapy

        -  At presentation with FN (fever and neutropenia) and during an initial inpatient
           observation period of 8 to 22 hours, empirical intravenous broad-spectrum antibiotics
           are given. Type and dosage are chosen by the treating physician.

        -  Patients randomized to continued intravenous antibiotics continue with these
           antibiotics.

        -  Patients randomized to oral antibiotics receive a combination of oral ciprofloxacin (25
           to 30 mg/kg/day, top dose 1500 mg/day) plus oral amoxicillin (65 to 80 mg/kg/day, top
           dose 2250 mg/day), both given in two doses per day.

        -  In both groups, the study gives guidelines (for certain situations) and rules (for other
           situations) when to change and when to stop antibiotics.

      Details on clinical and laboratory controls

        -  During antibiotic therapy, patients are seen daily, either as inpatients or as
           outpatients according to randomization. Complete blood counts are performed at least
           every second day.

        -  After stopping antibiotic therapy and until resolution of severe neutropenia (if
           applicable), patients are seen every other day, with a complete blood count.

        -  Patients randomized to outpatient management have the possibility to contact at any time
           of the day (and night) a pediatric oncologist in case of problems, in order to discuss
           necessity for emergency control and/or rehospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual goal for interventional part not achievable
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: No serious medical complication due to infection (death, treatment in ICU [Intensive Care Unit], potentially life-threatening complication) (non-inferiority-design, limit 3.5%)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Response without rehospitalization or changing randomized antibiotics (non-inferiority design, limit 10%)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved prediction of low-risk episodes of fever and neutropenia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of characteristics of low-risk episodes of fever and neutropenia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of characteristics of high-risk episodes of fever and neutropenia (observational study part)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Fever</condition>
  <condition>Neutropenia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continued inpatient i.v. antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch to outpatient p.o. antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin and amoxicillin</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Outpatient management</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i.v. antibiotics</intervention_name>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>inpatient management</intervention_name>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chemotherapy because of malignancy

          -  Severe neutropenia (absolute neutrophil count ≤ 0.5x10E9/L)

          -  Fever (axillary temperature ≥ 38.5°C once or ≥ 38.0°C during ≥ 2 hours)

          -  Able to swallow oral medication

          -  Written informed consent from patients and/or parents

        Exclusion Criteria:

          -  Status post myeloablative chemotherapy

          -  Diagnosis: acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or B-cell
             Non-Hodgkin lymphoma

          -  Bone marrow involvement by malignancy ≥ 25%

          -  Any comorbidity requiring hospitalization: [1] mean arterial blood pressure &lt; 50 mmHg
             (up to 10 years) / &lt; 60 mmHg (older than 10 years); [2] oxygen saturation &lt; 94% at
             room air; [3] radiologically defined pneumonia; [4] focal bacterial infection; [5]
             blood cultures taken at presentation reported positive at reassessment; [6] need for
             inpatient treatment or observation due to any other reason, as judged by the physician
             in charge

          -  Ever shaking chills

          -  Ever axillary temperature ≥ 39.5°C

          -  Antibacterial treatment before presentation with fever and neutropenia (except for
             prevention against Pneumocystis jiroveci [formerly P. carinii] pneumonia)

          -  Modification or de novo institution of a prophylaxis against P. jiroveci pneumonia

          -  Modification or de novo institution of a therapy with G-CSF or GM-CSF.

          -  Allergy to ciprofloxacin and/or amoxicillin

          -  Serum creatinine level above the upper limit of normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland A Ammann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Inselspital, CH-3010 Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Aebi, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Children's Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maja Beck-Popovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eveline SJM de Bont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Groningen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Kuehne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Nadal, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Niggli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arne Simon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Bonn, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Bodmer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hulya Ozsahin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Hematology/Oncology, University Children's Hospital, Geneva, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Bonn</city>
        <zip>D-53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital von Hauner</name>
      <address>
        <city>Munich</city>
        <zip>D-80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Hospital St. Hedwig</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>NL-9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, Children's Hospital</name>
      <address>
        <city>Lucerne</city>
        <zip>CH-6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology/Oncology, University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.spog.ch</url>
    <description>The Swiss Pediatric Oncology Group (SPOG) was the sponsor of this study.</description>
  </link>
  <reference>
    <citation>Ammann RA. SPOG 2003 FN: Risikobeurteilung und risikoadaptierte Behandlung bei Kindern und Jugendlichen mit Fieber in Neutropenie. Paediatrica 16(1): 28-31, 2005.</citation>
  </reference>
  <reference>
    <citation>Ammann RA, Simon A, de Bont ES. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer. 2005 Sep;45(3):244-7.</citation>
    <PMID>15747334</PMID>
  </reference>
  <results_reference>
    <citation>Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kühne T, Popovic MB, Lüthy AR, Aebi C. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010 Apr 20;28(12):2008-14. doi: 10.1200/JCO.2009.25.8988. Epub 2010 Mar 15.</citation>
    <PMID>20231680</PMID>
  </results_reference>
  <results_reference>
    <citation>Brack E, Bodmer N, Simon A, Leibundgut K, Kühne T, Niggli FK, Ammann RA. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer. 2012 Sep;59(3):423-30. doi: 10.1002/pbc.24076. Epub 2012 Jan 23.</citation>
    <PMID>22271702</PMID>
  </results_reference>
  <results_reference>
    <citation>Lüthi F, Leibundgut K, Niggli FK, Nadal D, Aebi C, Bodmer N, Ammann RA. Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatr Blood Cancer. 2012 Jul 15;59(1):90-5. doi: 10.1002/pbc.23277. Epub 2011 Aug 11.</citation>
    <PMID>21837771</PMID>
  </results_reference>
  <results_reference>
    <citation>Agyeman P, Aebi C, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kühne T, Beck Popovic M, Leibundgut K, Bodmer N, Ammann RA. Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study. Pediatr Infect Dis J. 2011 Jul;30(7):e114-9. doi: 10.1097/INF.0b013e318215a290.</citation>
    <PMID>21394050</PMID>
  </results_reference>
  <results_reference>
    <citation>Ammann RA, Niggli FK, Leibundgut K, Teuffel O, Bodmer N. Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropenia. PLoS One. 2014 Jul 14;9(7):e101696. doi: 10.1371/journal.pone.0101696. eCollection 2014.</citation>
    <PMID>25020130</PMID>
  </results_reference>
  <results_reference>
    <citation>Agyeman P, Kontny U, Nadal D, Leibundgut K, Niggli F, Simon A, Kronenberg A, Frei R, Escobar H, Kühne T, Beck-Popovic M, Bodmer N, Ammann RA. A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study. Pediatr Infect Dis J. 2014 Sep;33(9):e219-25. doi: 10.1097/INF.0000000000000326.</citation>
    <PMID>24618935</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2005</study_first_submitted>
  <study_first_submitted_qc>April 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2005</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <organization>Swiss Pediatric Oncology Group; Roland A Ammann, MD</organization>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>oral antibiotics</keyword>
  <keyword>outpatient treatment</keyword>
  <keyword>fever and neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

